Madrigal Pharmaceuticals (MDGL) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $9.22B and a free-cash-flow yield of -2.2%. Over the most recent reported fiscal year, revenue grew 432.1%. Nama's AI scorecard rates it Sell, 3.8 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Sell · 3.8/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Trailing · -15.5% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-38.4%
How far the last close sits under the highest price of the past five years.
Market cap
$9.22B
Trailing P/E
—
Price / book
14.7
Price / sales
6.5
FCF yield
-2.2%
Dividend yield
—
Gross margin
91.0%
Operating margin
-10.7%
Net margin
-10.9%
Revenue growth (YoY)
+432.1%
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
-1.0
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
MDGL earnings
Next report: Feb 18, 2027 (Q4 2026, EPS estimate $1.92).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 3, 2026
$1.83
-$0.87
+310.3%
$431.27M
Q2 2026
Jul 30, 2026
-$1.99
-$2.23
+10.8%
$364.25M
Q1 2026
May 6, 2026
-$1.38
-$4.14
+66.7%
$311.34M
Q4 2025
Feb 19, 2026
-$2.57
-$0.88
-192.1%
$321.08M
MDGL analyst price target
Median target $660.00 from 18 analysts, ranging $479.00 – $962.00.
Nama's AI scorecard currently rates Madrigal Pharmaceuticals Sell (3.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MDGL report earnings?
Madrigal Pharmaceuticals's next scheduled report is on Feb 18, 2027. Analysts expect EPS of $1.92.
What is the MDGL price target?
The median analyst price target from 18 analysts is $660.00, with a range of $479.00 – $962.00.
Is MDGL Shariah compliant?
Nama's AAOIFI-style screen reads Madrigal Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.